Structure-guided development of affinity probes for tyrosine kinases using chemical genetics

Nature Chemical Biology

Volumn 3, Issue 4, 2007, Pages 229-238

  Blair, Jimmy A ^a,b   Rauh, Daniel ^b,e   Kung, Charles ^b,f   Yun, Cai Hong ^c,d   Fan, Qi Wen ^b   Rode, Haridas ^e   Zhang, Chao ^b   Eck, Michael J ^c,d   Weiss, William A ^b   Shokat, Kevan M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e CHEMICAL GENOMICS CENTRE OF THE MAX PLANCK SOCIETY   (Germany)

^f NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 ACRYLAMIDO 4 ANILINOQUINAZOLINE; CYSTEINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GLYCINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL]ACRYLAMIDE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; REAGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIOENGINEERING; CELL ACTIVITY; CHEMICAL GENETICS; CONTROLLED STUDY; COVALENT BOND; CRYSTAL STRUCTURE; DOWNSTREAM PROCESSING; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TARGETING; EMBRYO; ENZYME STRUCTURE; MOLECULAR PROBE; MOUSE; NONHUMAN; ONCOGENE SRC; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; WILD TYPE;

PYRONIA TITHONUS;

AFFINITY LABELS; ANIMALS; BINDING SITES; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUTATION; NIH 3T3 CELLS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; SIGNAL TRANSDUCTION; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33947317223     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio866     Document Type: Article

References (50)

1. Cohen, P. Protein kinases-the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1, 309-315 (2002).
2. Knight, Z.A. & Shokat, K.M. Features of selective kinase inhibitors. Chem. Biol. 12, 621-637 (2005).
3. Kung, C., Kenski, D.M., Krukenberg, K., Madhani, H.D. & Shokat, K.M. Selective kinase inhibition by exploiting differential pathway sensitivity. Chem. Biol. 13, 399-407 (2006).
4. Ventura, J.J. et al. Chemical genetic analysis of the time course of signal transduction by JNK. Mol. Cell 21, 701-710 (2006).
5. Evans, M.J. & Cravatt, B.F. Mechanism-based profiling of enzyme families. Chem. Rev. 106, 3279-3301 (2006).
6. Shreder, K.R., Wong, M.S., Nomanbhoy, T., Leventhal, P.S. & Fuller, S.R. Synthesis of AX7593, a quinazoline-derived photoaffinity probe for EGFR. Org. Lett. 6, 3715-3718 (2004).
7. Yee, M.C., Fas, S.C., Stohlmeyer, M.M., Wandless, T.J. & Cimprich, K.A. A cell-permeable, activity-based probe for protein and lipid kinases. J. Biol. Chem. 280, 29053-29059 (2005).
8. Yuan, H. et al. Synthesis and activity of C11-modified wortmannin probes for PI3 kinase. Bioconjug. Chem. 16, 669-675 (2005).
9. Liu, Y. et al. Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase. Chem. Biol. 12, 99-107 (2005).
10. Liu, Y. et al. Structural basis for selective inhibition of Src family kinases by PP1. Chem. Biol. 6, 671-678 (1999).
11. Buzko, O. & Shokat, K.M. A kinase sequence database: sequence alignments and family assignment. Bioinformatics 18, 1274-1275 (2002).
12. Bishop, A.C. et al. A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature 407, 395-401 (2000).
13. Fry, D.W. et al. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc. Natl. Acad. Sci. USA 95, 12022-12027 (1998).
14. Singh, J. et al. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases. J. Med. Chem. 40, 1130-1135 (1997).
15. Cohen, M.S., Zhang, C., Shokat, K.M. & Taunton, J. Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science 308, 1318-1321 (2005).
16. Stamos, J., Sliwkowski, M.X. & Eigenbrot, C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 277, 46265-46272 (2002).
17. Fan, Q.W., Zhang, C., Shokat, K.M. & Weiss, W.A. Chemical genetic blockade of transformation reveals dependence on aberrant oncogenic signaling. Curr. Biol. 12, 1386-1394 (2002).
18. Tsou, H.R. et al. 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity. J. Med. Chem. 44, 2719-2734 (2001).
19. Seeliger, M.A. et al. High yield bacterial expression of active c-Abl and c-Src tyrosine kinases. Protein Sci. 14, 3135-3139 (2005).
20. Hennequin, L.F. et al. N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4- methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J. Med. Chem. 49, 6465-6488 (2006).
21. Yun, C.-H. et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell (in the press).
22. Heron, N.M. et al. SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors. Bioorg. Med. Chem. Lett. 16, 1320-1323 (2006).
23. Shewchuk, L. et al. Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase. J. Med. Chem. 43, 133-138 (2000).
24. Wood, E.R. et al. A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 64, 6652-6659 (2004).
25. Fry, D.W. Mechanism of action of erbB tyrosine kinase inhibitors. Exp. Cell Res. 284, 131-139 (2003).
26. Breitenlechner, C.B. et al. Crystal structures of active SRC kinase domain complexes. J. Mol. Biol. 353, 222-231 (2005).
27. Cowan-Jacob, S.W. et al. The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. Structure 13, 861-871 (2005).
28. Xu, W., Harrison, S.C. & Eck, M.J. Three-dimensional structure of the tyrosine kinase c-Src. Nature 385, 595-602 (1997).
29. Leftheris, K. et al. The discovery of orally active triaminotriazine aniline amides as inhibitors of p38 MAP kinase. J. Med. Chem. 47, 6283-6291 (2004).
30. Fry, D.W. et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 265, 1093-1095 (1994).
31. Pollack, V.A. et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J. Pharmacol. Exp. Ther. 291, 739-748 (1999).
32. Wakeling, A.E. et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 62, 5749-5754 (2002).
33. Fan, Q.W. et al. Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach. Cancer Res. 63, 8930-8938 (2003).
34. Smaill, J.B. et al. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3, 2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. J. Med. Chem. 43, 1380-1397 (2000).
35. Rasmussen, S.G. et al. Biophysical characterization of the cocaine binding pocket in the serotonin transporter using a fluorescent cocaine analogue as a molecular reporter. J. Biol. Chem. 276, 4717-4723 (2001).
36. Uchiyama, S., Santa, T., Okiyama, N., Fukushima, T. & Imai, K. Fluorogenic and fluorescent labeling reagents with a benzofurazan skeleton. Biomed. Chromatogr. 15, 295-318 (2001).
37. Jorissen, R.N. et al. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp. Cell Res. 284, 31-53 (2003).
38. Witucki, L.A. et al. Mutant tyrosine kinases with unnatural nucleotide specificity retain the structure and phospho-acceptor specificity of the wild-type enzyme. Chem. Biol. 9, 25-33 (2002).
39. Wissner, A. et al. 4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6, 7-dialkoxyquinazoline inhibitors. J. Med. Chem. 43, 3244-3256 (2000).
40. Lynch, T.J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004).
41. Paez, J.G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
42. Kobayashi, S. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786-792 (2005).
43. Pao, W. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73 (2005).
44. Engelman, J.A. et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J. Clin. Invest. 116, 2695-2706 (2006).
45. Inukai, M. et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res. 66, 7854-7858 (2006).
46. Carter, T.A. et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl. Acad. Sci. USA 102, 11011-11016 (2005).
47. Kobayashi, S. et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 65, 7096-7101 (2005).
48. Kwak, E.L. et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl. Acad. Sci. USA 102, 7665-7670 (2005).
49. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
50. DeLano, W.L. The PyMOL Molecular Graphics System (DeLano Scientific, San Carlos, California, USA, 2002).